Search
Cefminox
go.drugbank.com/drugs/DB09062ExperimentalCefminox (INN) is a second generation cephalosporin antibiotic. It is approved for use in Japan.
Categories: Antibacterials for Systemic Use, Antiinfectives for Systemic UsePhenacetin
go.drugbank.com/drugs/DB03783ApprovedWithdrawnPhenacetin was withdrawn from the Canadian market in June 1973 due to concerns regarding nephropathy (damage to or disease of the kidney).
Technetium Tc-99m tilmanocept
go.drugbank.com/drugs/DB09266ApprovedTechnetium Tc-99m tilmanocept is a radiopharmaceutical diagnostic imaging agent approved by the U.S. … Detecting sentinel lymph node (SLN) is clinically useful in the prognosis and management of the disease, as it is considered as the first lymph node that receives afferent lymphatic drainage from a primary
Aducanumab
go.drugbank.com/drugs/DB12274ApprovedInvestigational[A235668,A235720] Clinical trials showed a 23% relative difference between the experimental and placebo groups as determined by CDR; however, this is equivalent to an absolute difference of 0.4/18. … [A235720] Although aducanumab's approval represents the first drug treatment for Alzheimer's disease, the approval is conditional on further results.
Ensartinib
go.drugbank.com/drugs/DB14860ApprovedInvestigational[A265030] The drug is 10-fold more potent in the inhibition of the growth of ALK-positive lung cancer cell lines when compared to [crizotinib]. … when compared to [crizotinib].
Guanidine
go.drugbank.com/drugs/DB00536ApprovedIt is also used in laboratory research as a protein denaturant. … A strong organic base existing primarily as guanidium ions at physiological pH. It is found in the urine as a normal product of protein metabolism.
Nedosiran
go.drugbank.com/drugs/DB17635ApprovedInvestigationalNedosiran is an RNA interference targeting hepatic lactate dehydrogenase, the enzyme responsible for the conversion of glyoxylate to oxalate. … This approval is based on the favorable results from the pivotal phase 2 PHYOX<sup>TM</sup>2 and interim data from the ongoing phase 3 PHYOX<sup>TM</sup>3 clinical trials.[L48325]